The test uses fluid taken from patients to identify this complex, which may be associated with inflammation due to cartilage and spinal disc damage or degeneration. The patent includes diagnostic kit claims for detecting the Fibronectin and Aggrecan Complex and can be used to pinpoint the source of musculoskeletal pain.
More Articles on Pain Management:
8 Benchmarks for Low Back Pain Injections
Maintaining Quality at Pain Centers: Q&A With Dr. Edward Tavel of Pain Specialists of Charleston
Kentucky Society for Interventional Pain Physicians Tackles Opioid Prescribing
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
